Johnson & Johnson (JNJ) Position Lowered by Dowling & Yahnke LLC
Dowling & Yahnke LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 80,810 shares of the company’s stock after selling 620 shares during the period. Johnson & Johnson makes up about 1.1% of Dowling & Yahnke LLC’s portfolio, making the stock its 16th largest position. Dowling & Yahnke LLC’s holdings in Johnson & Johnson were worth $9,546,000 at the end of the most recent quarter.
Several other large investors also recently added to or reduced their stakes in the stock. Avalon Advisors LLC increased its stake in Johnson & Johnson by 32.7% in the first quarter. Avalon Advisors LLC now owns 410,880 shares of the company’s stock valued at $44,457,000 after buying an additional 101,250 shares during the last quarter. Fundsmith LLP boosted its stake in Johnson & Johnson by 24.1% in the second quarter. Fundsmith LLP now owns 3,704,693 shares of the company’s stock worth $449,379,000 after buying an additional 719,532 shares during the period. Shelton Capital Management boosted its stake in Johnson & Johnson by 17.5% in the second quarter. Shelton Capital Management now owns 58,181 shares of the company’s stock worth $7,057,000 after buying an additional 8,669 shares during the period. British Columbia Investment Management Corp boosted its stake in Johnson & Johnson by 1.0% in the second quarter. British Columbia Investment Management Corp now owns 1,649,232 shares of the company’s stock worth $200,052,000 after buying an additional 17,000 shares during the period. Finally, RKL Wealth Management LLC boosted its stake in Johnson & Johnson by 16.7% in the second quarter. RKL Wealth Management LLC now owns 43,943 shares of the company’s stock worth $5,167,000 after buying an additional 6,287 shares during the period. 64.13% of the stock is owned by institutional investors.
Johnson & Johnson (NYSE:JNJ) traded down 0.88% during trading on Monday, hitting $113.13. The company had a trading volume of 9,025,708 shares. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The stock has a market capitalization of $307.77 billion, a price-to-earnings ratio of 19.86 and a beta of 0.75. The company’s 50 day moving average price is $116.14 and its 200-day moving average price is $118.35.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. Johnson & Johnson had a return on equity of 25.30% and a net margin of 22.03%. The company had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same period in the previous year, the company posted $1.49 EPS. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post $6.72 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a dividend yield of 2.80%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. Johnson & Johnson’s payout ratio is presently 56.64%.
ILLEGAL ACTIVITY WARNING: “Johnson & Johnson (JNJ) Position Lowered by Dowling & Yahnke LLC” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/28/johnson-johnson-jnj-position-lowered-by-dowling-yahnke-llc.html.
A number of equities research analysts recently weighed in on JNJ shares. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price target on the stock in a research note on Monday, August 22nd. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price target on the stock in a research note on Friday, August 5th. BTIG Research restated a “neutral” rating on shares of Johnson & Johnson in a research note on Wednesday, September 7th. RBC Capital Markets set a $133.00 price target on Johnson & Johnson and gave the company a “buy” rating in a research note on Wednesday, November 9th. Finally, Credit Suisse Group AG restated a “neutral” rating and issued a $123.00 price target on shares of Johnson & Johnson in a research note on Monday, September 19th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus target price of $121.02.
In related news, Director Charles Prince acquired 875 shares of the firm’s stock in a transaction that occurred on Friday, October 21st. The shares were bought at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the purchase, the director now owns 26,520 shares in the company, valued at approximately $3,026,197.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.11% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.